At Eyecelerator 2025, Neurotech CEO Rich Small shares the story behind ENCELTO™, a first-in-class encapsulated cell-based gene therapy for the treatment of idiopathic MacTel, approved by the FDA for the treatment of adults. Unlike traditional injections, ENCELTO is designed for long-term delivery—and it’s already FDA approved. Learn how Neurotech is reshaping the future of retina care with innovation, logistics and patient-first thinking.
Secure your seat for the next Eyecelerator here: https://www.eyecelerator.com/aao2025-registration. The early bird window is open from July 23 through August 20.
